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Antibiotic stewardship: prescribing social norms
With a burgeoning world population, expansions 
in medical intervention, and intensiﬁ ed agriculture, 
the need for antibiotic stewardship is increasingly 
clear.1 Declining eﬃ  cacy of antimicrobial prophylaxis 
for surgery or chemotherapy,2 and emergence of 
pan-resistant pathogens,1 warn of a post-antibiotic era. 
In the evolutionary arms race of antimicrobial resistance, 
rejuvenating the neglected pipeline for new agents 
provides only a partial solution.3 The key challenge 
worldwide is translating awareness of resistance into 
eﬀ ective stewardship.1
In the past decade, the UK has made notable progress. 
A high media proﬁ le has provided political leverage to 
advance antimicrobial resistance up national health 
agendas, and surveillance systems for antibiotic 
consumption and resistance have been established.4,5 
National targets to reduce broad-spectrum antibiotic use 
have been associated with declines in Clostridium diﬃ  cile 
and meticillin-resistant Staphylococcus aureus.5,6 However, 
declining sensitivities to substitute antibiotics4 suggest 
that without reducing total antibiotic consumption, we 
might be replacing rather than eliminating resistances.7 
Sustaining progress will require a major shift in 
prescribing and consumption norms.
A particular challenge in reducing antibiotic use is the 
disconnect between individual behaviour and population-
level resistance. Avoiding overuse of a global common 
good requires making a diﬀ use and unrecognised 
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Figure: Total consumption of antibiotics for systemic use* (A) and mean annual change in consumption of antibiotics in primary care (B) by European 
country, 2000–14
Data from ESAC-Net (retrieved Dec 3, 2015).13 The UK is shown in red. *As deﬁ ned in the WHO/ATX index (2012). DDDs=deﬁ ned daily doses.
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social cost visible and felt. There is increasing interest in 
applying behavioural science, particularly in primary-care 
prescribing. In the UK, 80–90% of human antibiotic use 
occurs in the community, and large variation in prescribing 
rates are seen.5 In a recent UK survey of over 1000 general 
practitioners (GPs), 28% reported prescribing antibiotics 
several times a week when uncertain of their necessity.8
In The Lancet, Michael Hallsworth and colleagues9 
provide evidence that social norm feedback to prescribers 
can be an eﬀ ective method to reduce total antibiotic 
consumption in ambulatory care. Their national 
pragmatic randomised controlled trial (RCT) assessed two 
interventions targeting 1581 GP practices in England with 
the highest antibiotic prescribing rates in their areas. In the 
ﬁ rst intervention, GP practices in the intervention group 
received letters from England’s Chief Medical Oﬃ  cer, 
which highlighted that their practice had prescribing 
rates higher than 80% of neighbouring practices, and 
resources for supporting self-care and delayed antibiotic 
prescriptions. In the second intervention, original 
control and intervention groups were re-randomised to 
a patient education campaign (posters and leaﬂ ets sent 
to practice managers) or a control group. During the 
ﬁ rst intervention, the rate of antibiotic items dispensed 
per 1000 weighted population—the primary outcome 
measure—was 126·98 (95% CI 125·68–128·27) in 
the intervention group and 131·25 (130·33–132·16) 
in the control group (incidence rate ratio [IRR] 0·967, 
95% CI 0·957–0·977; p<0·0001). Over 6 months, this 
between group diﬀ erence of 4·27 (3·3%) equated to 
73 406 fewer antibiotic prescriptions. The patient-
oriented intervention did not yield a signiﬁ cant additional 
beneﬁ t (antibiotic items dispensed per 1000 population: 
135·00 [95% CI 133·77–136·22] in the patient-focused 
intervention group vs 133·98 [133·06–134·90] in the 
control group; IRR 1·01, 95% CI 1·00 to 1·02; p=0·105).
Ethical and logistical considerations mean that most 
antibiotic stewardship interventions are assessed by 
observational or quasi-experimental studies.10 The 
eﬃ  cient experimental design of this study strengthens 
conﬁ dence in causality. Reassuringly, the eﬀ ect size was 
congruent with previous investigations on antibiotic 
prescriber feedback, although contamination through 
changes in antibiotic prescribing in controls could 
have led to an underestimate. Controls for patient 
characteristics and historic antibiotic use minimised 
common sources of confounding in cluster RCTs.
The investigators did not assess the eﬀ ects of the 
interventions on microbiological (resistance) outcomes, 
and did not record data for appropriateness of antibiotic 
use or harms from underuse. However, previous national 
and international studies have linked large variation in 
primary-care antibiotic use to resistance.4,5,11 Furthermore, 
the largest eﬀ ects of the feedback intervention were 
during winter, and in macrolide and penicillin use: 
Sweden’s Strama programme showed that the restriction 
of common antimicrobial drugs for upper respiratory tract 
infections did not lead to an increase in complications.12 A 
more important limitation of Hallsworth and colleagues’ 
study is the short timescale of the intervention. It is not 
clear whether reiteration would be equally eﬀ ective and 
whether, given time, it would shift, or merely narrow, the 
national antibiotic prescribing distribution.
The national scale, pragmatic trial design, and low cost 
of the intervention suggest that social norm feedback 
could be eﬀ ective and cost-saving in other settings. 
However, we note strong caveats. First, in a universal 
health-care system, the transaction costs of obtaining, 
publicising, and comparing prescribing data are low. 
Surveillance systems in other countries are increasingly 
being established, but with multiple providers aligned 
to diﬀ erent sociodemographic or clinical populations, 
meaningful comparisons are likely to be diﬃ  cult. Second, 
eﬀ ectiveness depends upon the salience of social norms 
to practitioner and patient behaviour. The public and 
practitioners in the UK are a “prepared ﬁ eld” after two 
decades of battling health-care-associated infections 
and with high media interest in resistance.4,5 The absence 
of eﬀ ect reported for the patient-oriented intervention 
could reﬂ ect saturation in public awareness. The 
reputational cost of deviance from prescribing norms, 
and use of a high-proﬁ le messenger (the Chief Medical 
Oﬃ  cer) might not provide as much leverage elsewhere. 
Third, social norms are only helpful where they converge 
with policy aims. A key message from behavioural 
sciences is that social factors aﬀ ecting antibiotic 
prescribing and consumption norms are complex and 
context dependent.1,11 Where health insurance or out-of-
pocket expenditures predominate, doctor reputation and 
income depend upon answering patients’ expectations 
for antibiotics.2 If patients can “shop” for antibiotics over 
the counter, a “race to the bottom” can occur.1
It is also important to see the eﬀ ect size in perspective. 
The investigators highlight that their feedback 
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About 214 million acute cases of malaria occur 
worldwide every year, the majority of which are in 
Africa.1 Although usually mosquito-borne, these 
Plasmodium parasite infections are also transmitted 
by blood transfusion in endemic countries. In highly 
endemic areas, transfusion-transmitted malaria 
can result in no symptoms or fairly mild symptoms 
if recipients have previous exposure and are semi-
immune. However, for those with no immunity, a s 
is often the case for young children, transfusion-
transmitted malaria poses a very serious risk. 
Furthermore, because malaria risk is regional in many 
parts of Africa, non-immune recipients in less risky 
areas can be infected by donors who have spent time 
in endemic areas. In non-endemic countries, a risk of 
transfusion-transmitted malaria exists when blood 
donors have travelled to endemic countries, but this 
low risk is addressed eﬀ ectively by either testing the 
Transfusion-transmitted malaria: is hope around the corner? 
intervention could reduce primary-care prescribing in 
England by 0·85%, against a 5-year aim of reducing 
prescribing in primary care by 4%.5 Between 2000 and 
2014, UK primary-care antibiotic use expanded by 46%, 
from 14·3 to 20·9 deﬁ ned daily doses per 1000 inhabitant-
days.13 During the same period, antibiotic use fell in several 
European countries, and UK consumption is now twice 
that of the Netherlands (ﬁ gure).13 Inpatient consumption 
also continues to increase.4,5 Minimising discordance 
between public or practitioner norms and policy could 
be expected to sharpen eﬃ  cacy and sustainability of 
stewardship. The feedback intervention was notably 
cheaper than NHS England’s potentially divisive ﬁ nancial 
incentives for areas that reduce total antibiotic use by 1%.5 
The ethical principle of least restrictive means suggests 
self-regulation is preferable to top-down mandates. 
However, where externalities are high and evidence 
compelling (eg, seat-belt legislation or smoking bans), 
government may need to act early to create new norms 
before they are widely accepted.
Hallsworth and colleagues make a clear case for 
integrating behavioural approaches into antibiotic 
stewardship, but interventions will need tailoring to 
regional contexts. The urgent, worldwide, and ecological 
nature of antibiotic resistance suggests that behavioural 
interventions should complement, rather than replace, 
top-down strategies.
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